Early Warning Report issued pursuant to National Instrument 62-103
acquisition of shares of Amorfix Life Sciences

TSX: AMF

TORONTO, Aug. 16 /CNW/ - This press release is being disseminated as required by National Instrument 62-103 The Early Warning System and Related Take Over Bids and Insider Reporting Issues in connection with the filing of an early warning report (the "Early Warning Report") regarding the acquisition of securities of Amorfix Life Sciences Ltd. ("Amorfix") by the Interinvest Group of Companies ("Interinvest") of Boston, Massachusetts.

On August 16, 2010, Interinvest reported that it had acquired direction or control through open market purchases of a total of 4,862,550 common shares of Amorfix representing 10.0% of the issued and outstanding common shares. Dr. Hans Black, the Chairman of Interinvest is also a director of Amorfix. Both he and Mr. Michael R. Sonnenreich, also a director of Amorfix, hold common shares of Amorfix that are included in the 10.0% as they are held within Interinvest accounts.

"We appreciate this strong endorsement of Amorfix by Interinvest and our directors who share our vision and confidence in our product pipeline and its future prospects," said Dr. Robert Gundel, Chief Executive Officer of Amorfix.

The common shares were acquired for investment purposes and Interinvest may increase or decrease its direction or control depending on market or other conditions.

A copy of the Early Warning Report will be filed on www.SEDAR.com.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's disease. Amorfix utilizes its computational discovery platform, ProMIS(TM), to predict novel Disease Specific Epitopes ("DSE") on the molecular surface of misfolded proteins. Amorfix's lead therapeutic programs include antibodies and vaccines to DSEs in ALS, Alzheimer's disease and cancer. Amorfix's proprietary Epitope Protection(TM) (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a normal sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated Beta-Amyloid in brain tissue and blood of animal models of Alzheimer's disease, months prior to observable amyloid formation, and human blood screening tests for Alzheimer's and early liver cancer detection. For more information about Amorfix, visit www.amorfix.com.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Amorfix Life Sciences Ltd.

For further information: For further information: Dr. Robert Gundel, President and Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6957, Fax: (416) 847-6899, bob.gundel@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899, james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890